Skip to main content

Danielle Marie Brander

Associate Professor of Medicine
Medicine, Hematologic Malignancies and Cellular Therapy
DUMC Box 3961, Durham, NC 27710
2400 Pratt St Suite 5000, Durham, NC 27710

Selected Grants


Short Title Phase 3 Sonrotoclax + Zanubrutinib compared with Ven + Obinutuzumab in Patients untreated CLL

Clinical TrialPrincipal Investigator · Awarded by BeiGene USA, Inc. · 2024 - 2029

An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients with B-cell Malignancies

Clinical TrialPrincipal Investigator · Awarded by BeiGene USA, Inc. · 2023 - 2028

Hematology & Transfusion Medicine (T32)

Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 1975 - 2026

DFCI Obinutuzumab and Ibrutinib Protocol # 15-283

Clinical TrialPrincipal Investigator · Awarded by Dana-Farber Cancer Institute · 2017 - 2022

Phase III study of ACP-196 vs Ibrutinib in High Risk CLL

Clinical TrialPrincipal Investigator · Awarded by Acerta Pharma · 2016 - 2022

Phase 3 Study of Ublituximab in combination with Ibrutinib compared to Ibrutinib Alone in CLL pts.

Clinical TrialPrincipal Investigator · Awarded by TG Therapeutics, Inc · 2015 - 2022

Novartis: CVAY736Y2102 Ph1b VAY736 and Ibrutinib patients with CLL on Ibrutinib therapy

Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2020 - 2021

Screening protocol to determine high risk cytogenetic features in previously treated CLL

Clinical TrialPrincipal Investigator · Awarded by TG Therapeutics, Inc · 2016 - 2017

A Phase II Study of PNT2258 in Patients with Richter's Transformation (RT).

Clinical TrialPrincipal Investigator · Awarded by ProNAi Therapeutics, Inc. · 2016 - 2017

MedImmune CD-ON-CAT-8015-1053

Clinical TrialPrincipal Investigator · Awarded by MedImmune, Inc. · 2015 - 2017

A Phase I Trial of a Bcl-2 inhibitor and a MEK inhibitor for patients with relapsed indolent B-NHL

ResearchPrincipal Investigator · Awarded by Lymphoma Research Foundation of America · 2014 - 2016

External Relationships


  • AbbVie Pharmaceuticals
  • Alliance for Clinical Trials in Oncology
  • ArQule/Merck
  • AstraZeneca
  • BeiGene
  • AbbVie Pharmaceuticals
  • Alliance for Clinical Trials in Oncology
  • ArQule/Merck
  • AstraZeneca
  • BeiGene
  • CLL Society
  • Clinical Care Options
  • DTRM Biopharma
  • Dava Oncology
  • Genentech, Inc (Roche Holding)
  • Juno/celgene/BMS
  • NCCN
  • Newave Pharma
  • Pharmacyclics
  • Prime Oncology
  • TG Therapeutics
  • WebMD/Medscape
  • catapult
  • nurix

This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.